Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Alexandra Lea"'
Autor:
Marie-Lise Schläppy, Jennifer Loder, Jodi Salmond, Alexandra Lea, Angela J. Dean, Chris M. Roelfsema
Publikováno v:
Frontiers in Marine Science, Vol 4 (2017)
The benefit of engaging volunteers in marine citizen science projects goes beyond generation of data and has intrinsic value with regards to community capacity-building and education. Yet, despite the documented benefits of citizen science, there can
Externí odkaz:
https://doaj.org/article/a89a4937194a4fceae3842e023247263
Autor:
Chris Roelfsema, Ruth Thurstan, Maria Beger, Christine Dudgeon, Jennifer Loder, Eva Kovacs, Michele Gallo, Jason Flower, K-le Gomez Cabrera, Juan Ortiz, Alexandra Lea, Diana Kleine
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0163407 (2016)
Subtropical reefs provide an important habitat for flora and fauna, and proper monitoring is required for conservation. Monitoring these exposed and submerged reefs is challenging and available resources are limited. Citizen science is increasing in
Externí odkaz:
https://doaj.org/article/09bbe784867c4b419f43d88be7f4f619
Autor:
Chiara Maria Lavinia Loeffler, Omar S. M. El Nahhas, Hannah Sophie Muti, Zunamys I. Carrero, Tobias Seibel, Marko van Treeck, Didem Cifci, Marco Gustav, Kevin Bretz, Nadine T. Gaisa, Kjong-Van Lehmann, Alexandra Leary, Pier Selenica, Jorge S. Reis-Filho, Nadina Ortiz-Bruechle, Jakob Nikolas Kather
Publikováno v:
BMC Biology, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Homologous recombination deficiency (HRD) is recognized as a pan-cancer predictive biomarker that potentially indicates who could benefit from treatment with PARP inhibitors (PARPi). Despite its clinical significance, HRD testing
Externí odkaz:
https://doaj.org/article/003303862b20434e84941368c6c014a7
Autor:
Aurélie Moniot, Christophe Schneider, Laure Chardin, Elisa Yaniz-Galende, Catherine Genestie, Marion Etiennot, Aubéri Henry, Coralie Drelon, Audrey Le Formal, Benoit Langlois, Laurence Venat, Christophe Louvet, Laure Favier, Alain Lortholary, Dominique Berton-Rigaud, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Coraline Dubot, Jean Emmanuel Kurtz, Nathalie Bonichon Lamichhane, Éric Pujade-Lauraine, Albin Jeanne, Alexandra Leary, Stéphane Dedieu
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract Background Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC, many patients will relapse and
Externí odkaz:
https://doaj.org/article/dd3b485e8ca3415e9aedea04cb9e8214
Autor:
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Pilar Barretina-Ginesta, Marta Gil-Martin, Elena Garralda, Joaquim Bosch-Barrera, Teresa Morán, Paloma Martin-Martorell, Ernest Nadal, Pere Gascón, Jordi Rodon, Jose M Lizcano, Pau Muñoz-Guardiola, Gemma Fierro-Durán, Oriol Pedrós-Gámez, Héctor Pérez-Montoyo, Marc Yeste-Velasco, Marc Cortal, Antonio Pérez-Campos, Jose Alfon, Carles Domenech, Alejandro Pérez-Fidalgo, Ana Oaknin
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Carboplatin and paclitaxel (CP) have been the standard of care for advanced/recurrent endometrial cancer (EC) for many years. However, this chemotherapy combination shows limited efficacy and recurrences often occur in less than 1
Externí odkaz:
https://doaj.org/article/e9af8aa9cdf44687a3777adf7751ad39
Autor:
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to a
Externí odkaz:
https://doaj.org/article/afb66d701040478ba283ee012404613d
Autor:
Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimu
Externí odkaz:
https://doaj.org/article/be397a2c9d104c41b010a59bc9500941
Autor:
Etienne Rouleau, Ana Oaknin, Christophe Klein, Alexandra Leary, Sebastien Gouy, Patricia Pautier, Catherine Genestie, Amandine Maulard, Judith Michels, Marco de Bruyn, Emeline Colomba-Blameble, Annechien Plat, Juan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, Audrey Le Formal, Elodie Edmond, Maëva Moreau
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking.Methods We compared the imm
Externí odkaz:
https://doaj.org/article/07f2752f80f74236aa5694863f592740
Autor:
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, Isabelle Ray-Coquard, Margarita Romeo, Pilar Barretina-Ginesta, Marta Gil-Martin, Elena Garralda, Joaquim Bosch-Barrera, Teresa Morán, Paloma Martin-Martorell, Ernest Nadal, Pere Gascón, Jordi Rodon, Jose M Lizcano, Pau Muñoz-Guardiola, Gemma Fierro-Durán, Oriol Pedrós-Gámez, Héctor Pérez-Montoyo, Marc Yeste-Velasco, Marc Cortal, Antonio Pérez-Campos, Jose Alfon, Carles Domenech, Alejandro Pérez-Fidalgo, Ana Oaknin
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/89e1d4a9c33c48d7a1f7222dc8a7a449
Autor:
Cyril Roussel-Simonin, Felix Blanc-Durand, Roseline Tang, Damien Vasseur, Audrey Le Formal, Laure Chardin, Elisa Yaniz, Sébastien Gouy, Amandine Maulard, Stéphanie Scherier, Claire Sanson, Ludovic Lacroix, Sophie Cotteret, Lea Mauny, François Zaccarini, Etienne Rouleau, Alexandra Leary
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-9 (2023)
Abstract Background Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor
Externí odkaz:
https://doaj.org/article/16f627eaf07e4fe8ab803da24e0b8223